Tabriz University of Medical Sciences Journal of Research in Clinical Medicine 2717-0616 14 1 2026 01 01 A Comprehensive Review of the Novel Treatments of Acromegaly: A Narrative Review 35121 35121 10.34172/jrcm.35121 EN Halimeh Amirazad https://orcid.org/0000-0003-0719-4357 Amir Bahrami https://orcid.org/0000-0002-4735-1196 Haleh Darbandi https://orcid.org/0009-0001-2290-1104 Mostafa Najafipour https://orcid.org/0000-0002-9831-933X Farzad Najafipour https://orcid.org/0000-0003-1950-0702 REVIEW 10.34172/jrcm.35121 2024 10 06 2025 08 24 Acromegaly is a rare and heterogeneous endocrine disorder primarily caused by growth hormone-secreting pituitary adenomas. A l t h o u g h c u r r e n t therapeutic approaches, including surgery, medical therapies, and recently approved drugs, have significantly improved disease management, a considerable proportion of patients continue to exhibit persistent disease activity or treatment resistance. Therefore, the development of innovative therapeutic strategies remains essential, including new drug formulations and novel agents currently under investigation. Advances in pharmacological technologies have enhanced the efficacy and safety of acromegaly treatments. Moreover, identification of genetic alterations may facilitate early diagnosis, targeted screening, and risk assessment among affected families. Recent research has highlighted the important role of microRNAs (miRNAs) in acromegaly, particularly in regulating genes involved in pituitary tumorigenesis and resistance to treatment, especially resistance to first-generation somatostatin receptor ligands.